Cargando…

Arrhythmia Monitoring for Risk Stratification in Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy, presenting significant clinical heterogeneity. Arrhythmia risk stratification and detection are critical components in the evaluation and management of all cases of HCM. The 2020 American Heart Association/American Colleg...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Darson, Li, Christopher O.Y., Ong, Kevin, Parsa, Ashkan, Weissler-Snir, Adaya, Geske, Jeffrey B., Laksman, Zachary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039556/
https://www.ncbi.nlm.nih.gov/pubmed/35495864
http://dx.doi.org/10.1016/j.cjco.2022.01.001
_version_ 1784694154892148736
author Du, Darson
Li, Christopher O.Y.
Ong, Kevin
Parsa, Ashkan
Weissler-Snir, Adaya
Geske, Jeffrey B.
Laksman, Zachary
author_facet Du, Darson
Li, Christopher O.Y.
Ong, Kevin
Parsa, Ashkan
Weissler-Snir, Adaya
Geske, Jeffrey B.
Laksman, Zachary
author_sort Du, Darson
collection PubMed
description Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy, presenting significant clinical heterogeneity. Arrhythmia risk stratification and detection are critical components in the evaluation and management of all cases of HCM. The 2020 American Heart Association/American College of Cardiology HCM guidelines provide new recommendations for periodic 24-48-hour ambulatory electrocardiogram monitoring to screen for atrial and ventricular arrhythmias. A strategy of more frequent or prolonged monitoring would lead to earlier arrhythmia recognition and the potential for appropriate treatment. However, whether such a strategy in patients with HCM results in improved outcomes is not yet established. The available evidence, knowledge gaps, and potential merits of such an approach are reviewed. Cardiac implantable electronic devices provide an opportunity for early arrhythmia detection, with the potential to enable early management strategies in order to improve outcomes.
format Online
Article
Text
id pubmed-9039556
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-90395562022-04-27 Arrhythmia Monitoring for Risk Stratification in Hypertrophic Cardiomyopathy Du, Darson Li, Christopher O.Y. Ong, Kevin Parsa, Ashkan Weissler-Snir, Adaya Geske, Jeffrey B. Laksman, Zachary CJC Open Review Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy, presenting significant clinical heterogeneity. Arrhythmia risk stratification and detection are critical components in the evaluation and management of all cases of HCM. The 2020 American Heart Association/American College of Cardiology HCM guidelines provide new recommendations for periodic 24-48-hour ambulatory electrocardiogram monitoring to screen for atrial and ventricular arrhythmias. A strategy of more frequent or prolonged monitoring would lead to earlier arrhythmia recognition and the potential for appropriate treatment. However, whether such a strategy in patients with HCM results in improved outcomes is not yet established. The available evidence, knowledge gaps, and potential merits of such an approach are reviewed. Cardiac implantable electronic devices provide an opportunity for early arrhythmia detection, with the potential to enable early management strategies in order to improve outcomes. Elsevier 2022-01-07 /pmc/articles/PMC9039556/ /pubmed/35495864 http://dx.doi.org/10.1016/j.cjco.2022.01.001 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Du, Darson
Li, Christopher O.Y.
Ong, Kevin
Parsa, Ashkan
Weissler-Snir, Adaya
Geske, Jeffrey B.
Laksman, Zachary
Arrhythmia Monitoring for Risk Stratification in Hypertrophic Cardiomyopathy
title Arrhythmia Monitoring for Risk Stratification in Hypertrophic Cardiomyopathy
title_full Arrhythmia Monitoring for Risk Stratification in Hypertrophic Cardiomyopathy
title_fullStr Arrhythmia Monitoring for Risk Stratification in Hypertrophic Cardiomyopathy
title_full_unstemmed Arrhythmia Monitoring for Risk Stratification in Hypertrophic Cardiomyopathy
title_short Arrhythmia Monitoring for Risk Stratification in Hypertrophic Cardiomyopathy
title_sort arrhythmia monitoring for risk stratification in hypertrophic cardiomyopathy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039556/
https://www.ncbi.nlm.nih.gov/pubmed/35495864
http://dx.doi.org/10.1016/j.cjco.2022.01.001
work_keys_str_mv AT dudarson arrhythmiamonitoringforriskstratificationinhypertrophiccardiomyopathy
AT lichristopheroy arrhythmiamonitoringforriskstratificationinhypertrophiccardiomyopathy
AT ongkevin arrhythmiamonitoringforriskstratificationinhypertrophiccardiomyopathy
AT parsaashkan arrhythmiamonitoringforriskstratificationinhypertrophiccardiomyopathy
AT weisslersniradaya arrhythmiamonitoringforriskstratificationinhypertrophiccardiomyopathy
AT geskejeffreyb arrhythmiamonitoringforriskstratificationinhypertrophiccardiomyopathy
AT laksmanzachary arrhythmiamonitoringforriskstratificationinhypertrophiccardiomyopathy